ASCL1 and prostate adenocarcinoma: Taken together, these insights into ASCL1 vs. NEUROD1 expression within NEPC and SYP expression in PRAD argue for a standardized IHC panel-based approach using ASCL1, NEUROD1, INSM1, and SYP, in conjunction with histomorphological assessment, to add greater precision to the diagnosis and treatment of NEPC.